Doxorubicin Plus Sorafenib in Treatment of Advanced Hepatocellular Carcinoma Reply

被引：3
作者：
Abou-Alfa, Ghassan [1 ]
Capanu, Marinela [2 ]
Saltz, Leonard [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA
来源：
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2011年 / 305卷 / 08期
关键词：
PHASE-III;
D O I：
10.1001/jama.2011.160
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：781 / 781
页数：1
相关论文
共 4 条
  • [1] Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin
    Gish, Robert G.
    Porta, Camillo
    Lazar, Lucian
    Ruff, Paul
    Feld, Ronald
    Croitoru, Adina
    Feun, Lynn
    Jeziorski, Krzysztof
    Leighton, John
    Gallo, Jose
    Kennealey, Gerard T.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (21) : 3069 - 3075
  • [2] Sorafenib in advanced hepatocellular carcinoma
    Llovet, Josep M.
    Ricci, Sergio
    Mazzaferro, Vincenzo
    Hilgard, Philip
    Gane, Edward
    Blanc, Jean-Frederic
    Cosme de Oliveira, Andre
    Santoro, Armando
    Raoul, Jean-Luc
    Forner, Alejandro
    Schwartz, Myron
    Porta, Camillo
    Zeuzem, Stefan
    Bolondi, Luigi
    Greten, Tim F.
    Galle, Peter R.
    Seitz, Jean-Francois
    Borbath, Ivan
    Haussinger, Dieter
    Giannaris, Tom
    Shan, Minghua
    Moscovici, Marius
    Voliotis, Dimitris
    Bruix, Jordi
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (04) : 378 - 390
  • [3] Design and endpoints of clinical trials in hepatocellular carcinoma
    Llovet, Josep M.
    Di Bisceglie, Adrian M.
    Bruix, Jordi
    Kramer, Barnett S.
    Lencioni, Riccardo
    Zhu, Andrew X.
    Sherman, Morris
    Schwartz, Myron
    Lotze, Michael
    Talwalkar, Jayant
    Gores, Gregory J.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (10): : 698 - 711
  • [4] A randomized phase III study of doxorubicin versus cisplatin/interferon α-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma
    Yeo, W
    Mok, TS
    Zee, B
    Leung, TWT
    Lai, PBS
    Lau, WY
    Koh, J
    Mo, FKF
    Yu, SCH
    T Chan, A
    Hui, P
    Ma, B
    Lam, KC
    Ho, WM
    Wong, HT
    Tang, A
    Johnson, PJ
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (20): : 1532 - 1538
1